- Home
- LGCY vs SNTI Comparison
LGCY vs SNTI Comparison
Compare LGCY & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCY
- SNTI
- Stock Information
- Founded
- LGCY 2009
- SNTI 2016
- Country
- LGCY United States
- SNTI United States
- Employees
- LGCY N/A
- SNTI N/A
- Industry
- LGCY
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- LGCY
- SNTI Health Care
- Exchange
- LGCY NYSE
- SNTI Nasdaq
- Market Cap
- LGCY 89.1M
- SNTI 85.3M
- IPO Year
- LGCY 2024
- SNTI N/A
- Fundamental
- Price
- LGCY $9.04
- SNTI $3.14
- Analyst Decision
- LGCY Strong Buy
- SNTI Strong Buy
- Analyst Count
- LGCY 2
- SNTI 1
- Target Price
- LGCY $10.65
- SNTI $12.00
- AVG Volume (30 Days)
- LGCY 63.4K
- SNTI 27.9K
- Earning Date
- LGCY 05-15-2025
- SNTI 05-06-2025
- Dividend Yield
- LGCY N/A
- SNTI N/A
- EPS Growth
- LGCY 21.53
- SNTI N/A
- EPS
- LGCY 0.62
- SNTI N/A
- Revenue
- LGCY $58,970,210.00
- SNTI N/A
- Revenue This Year
- LGCY $33.77
- SNTI N/A
- Revenue Next Year
- LGCY $24.88
- SNTI N/A
- P/E Ratio
- LGCY $14.53
- SNTI N/A
- Revenue Growth
- LGCY 37.92
- SNTI N/A
- 52 Week Low
- LGCY $3.60
- SNTI $1.52
- 52 Week High
- LGCY $10.37
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- LGCY N/A
- SNTI 44.57
- Support Level
- LGCY N/A
- SNTI $3.03
- Resistance Level
- LGCY N/A
- SNTI $3.50
- Average True Range (ATR)
- LGCY 0.00
- SNTI 0.22
- MACD
- LGCY 0.00
- SNTI 0.00
- Stochastic Oscillator
- LGCY 0.00
- SNTI 23.40
About LGCY LEGACY EDUCATION INC
Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.